Inhibitor of differentiation proteins do not influence prognosis of biliary tract cancer

To investigate the expression and clinical relevance of inhibitor of differentiation (ID) proteins in biliary tract cancer. ID protein expression was analyzed in 129 samples from patients with advanced biliary tract cancer (BTC) (45 extrahepatic, 50 intrahepatic, and 34 gallbladder cancers), compare...

Full description

Saved in:
Bibliographic Details
Published in:World journal of gastroenterology : WJG 2013-12, Vol.19 (48), p.9334-9342
Main Authors: Harder, Jan, Müller, Michael J, Fuchs, Matthias, Gumpp, Vera, Schmitt-Graeff, Annette, Fischer, Richard, Frank, Melanie, Opitz, Oliver, Hasskarl, Jens
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Bile Duct Neoplasms - chemistry
Bile Duct Neoplasms - pathology
Bile Duct Neoplasms - therapy
Bile Ducts, Extrahepatic - chemistry
Bile Ducts, Extrahepatic - pathology
Bile Ducts, Intrahepatic - chemistry
Bile Ducts, Intrahepatic - pathology
Brief
Cholangiocarcinoma - chemistry
Cholangiocarcinoma - pathology
Cholangiocarcinoma - therapy
Female
Gallbladder Neoplasms - chemistry
Gallbladder Neoplasms - pathology
Gallbladder Neoplasms - therapy
Humans
Immunohistochemistry
Inhibitor of Differentiation Protein 1 - analysis
Inhibitor of Differentiation Protein 2 - analysis
Inhibitor of Differentiation Proteins - analysis
Kaplan-Meier Estimate
Male
Middle Aged
Multivariate Analysis
Neoplasm Grading
Neoplasm Proteins - analysis
Neoplasm Staging
Predictive Value of Tests
Proportional Hazards Models
Retrospective Studies
Risk Factors
Time Factors
Treatment Outcome
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To investigate the expression and clinical relevance of inhibitor of differentiation (ID) proteins in biliary tract cancer. ID protein expression was analyzed in 129 samples from patients with advanced biliary tract cancer (BTC) (45 extrahepatic, 50 intrahepatic, and 34 gallbladder cancers), compared to normal controls and correlated with clinical an pathological parameters. ID1-3 proteins are frequently overexpressed in all BTC subtypes analyzed. No correlation between increased ID protein expression and tumor grading, tumor subtype or treatment response was detected. Survival was influenced primary tumor localization (extrahepatic vs intrahepatic and gall bladder cancer, OS 1.5 years vs 0.9 years vs 0.7 years, P = 0.002), by stage at diagnosis (OS 2.7 years in stage I vs 0.6 years in stage IV, P < 0.001), resection status and response to systemic chemotherapy. In a multivariate model, ID protein expression did not correlate with clinical prognosis. Nevertheless, there was a trend of shorter OS in patients with loss of cytoplasmic ID4 protein expression (P = 0.076). ID protein expression is frequently deregulated in BTC but does not influence clinical prognosis. Their usefulness as prognostic biomarkers in BTC is very limited.
ISSN:1007-9327
2219-2840
DOI:10.3748/wjg.v19.i48.9334